NRM was defined as a death not related to disease. Neutrophil recovery was defined as an absolute neutrophil count of at least 500 cells/mm3 for three consecutive time points. Platelet recovery was defined as a count of at least 20 000 platelets/mm3 without transfusion support. Acute GVHD (aGVHD) was defined in accordance with standard criteria [12]. Chronic GVHD (cGVHD)

was evaluated in patients surviving VS-4718 for more than 100 days after allo-HCT and was classified into limited or extensive type [13]. Statistical analysis If the disease for which the patient underwent transplantation was present at the time of death or found at autopsy, we defined disease relapse/progression as the primary cause of death. Unadjusted survival probabilities were estimated CP673451 purchase using the Kaplan

and Meier method and compared using the log-rank tests. Cumulative incidence curves were used in a competing-risks model to calculate the probability of aGVHD, cGVHD and NRM [14]. For neutrophil and platelet recovery, death before neutrophil or platelet recovery was the competing event; for GVHD, death without GVHD and relapse were the competing events; and, for NRM, relapse was the competing event. In order to examine the impact of cGVHD on survival, we performed a OICR-9429 in vivo landmark analysis, which divided patients according to their prior history of cGVHD at 6 months post-transplant [15]. We excluded from landmark analysis patients who died or relapsed less than 6 months after transplant, and did not use the information on whether or not patients developed cGVHD 6 months after transplant. Multivariable analysis of prognostic factors for the primary outcome could not be conducted due to lack of statistical power. Instead, we performed a landmark analysis, which divided patients according to the significant pre-transplant factors and their prior history of cGVHD at 6 months post-transplant. All P values were 2-tailed and considered statistically significant Atezolizumab order if the values

were less than 0.05. All statistical analyses were performed using the PASW Statistics17.0 (SPSS Inc, Chicago, IL, USA) and the statistical software environment R, version 2.9.1. Results The baseline characteristics of the patients are shown in Table 1. Table 1 Baseline characteristics of study participants Variable n (%) Median (Range) Male sex 24 (57.1)   Diagnosis        de novo AML 17 (40.5)      ALL 12 (28.6)      CML-AP 2 (4.8)      MDS overt AML 10 (23.8)      PCL 1 (2.4)   Cytogenetics        Intermediate 17      Poor 22   ECOG PS        0 2 (4.8)      1 25 (59.5)      2 7 (16.7)      3 8 (19.0)   Status at allo-HCT        Primary refractory/Refractory relapse/Untreated MDS overt AML 7/32/3   No. chemo regimens prior allo-HCT   6 (0-18) Time from diagnosis to allo-HCT (days)   319 (23-3738) Marrow blasts at allo-HCT   26.0 (0.2-100) Conditioning regimen        Intensified 9 (21.4)      Standard 12 (28.6)      Reduced-intensity 7 (16.7)      Reduced-intensity + cytoreductive chemotherapy 14 (33.